title: [Comparison research with icariin and genistein by anti-inflammatory reaction and angiogenesis pathway to inhibit bone loss on ovariectomized rats].
abstract: OBJECTIVE
  Through researching the relationship among osteoporosis and inflammatory reaction besides angiogenesis, to compare pharmacological differences between icariin and genistein to inhibit bone loss.
  
  
  METHODS
  6 months old female SD rats were randomly divided into SHAM group, model group, ICA group, GEN group and E group. The bone mineral density of total, femur and lumbar, serum OC, TRACP 5b, IL-6 and VEGF, biomechanics of femur and tibia microarchitecture were analyzed.
  
  
  RESULTS
  Compared with SHAM group, model group of body weight, uterine weight, bone mineral density of total, femur and lumbar, serum OC, TRACP 5b, IL-6 and VEGF, biomechanics of femur and lumbar and tibia microarchitecture were significantly changed (P < 0.05). Compared with model group, ICA group of body weight, bone mineral density of total and femur, serum TRACP 5b and femural biomechanics were significantly changed (P < 0.05). GEN group of bone mineral density of total, femur and lumbar, serum OC, TRACP 5b, IL-6 and VEGF, biomechanics of femur and lumbar and tibia microarchitecture were significantly changed (P < 0.05).
  
  
  CONCLUSIONS
  Icariin inhibits bone loss on model rat through suppressing bone resorption. Genistein prevents bone loss on model rat by the pathway of inhibiting inflammatory reaction, activating angiogenesis, enhancing bone formation and inhibiting bone resorption. Moreover, pharmacological activity of genistein is more potential than icariin.
authors.forename: Kui
authors.initials: K
authors.lastname: Cheng
authors.forename: Ke-Ming
authors.initials: KM
authors.lastname: Chen
authors.forename: Bao-Feng
authors.initials: BF
authors.lastname: Ge
authors.forename: Ping
authors.initials: P
authors.lastname: Zhen
authors.forename: Yu-Hai
authors.initials: YH
authors.lastname: Gao
authors.forename: Hui-Ping
authors.initials: HP
authors.lastname: Ma
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000284:Administration, Oral; D043925:Angiogenesis Inducing Agents / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001862:Bone Resorption / Q000473:pathology / Q000517:prevention & control*; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology; D034181:Epimedium / Q000737:chemistry; D007887:Fabaceae / Q000737:chemistry; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D019833:Genistein / Q000494:pharmacology*; D015850:Interleukin-6 / Q000097:blood; D007527:Isoenzymes / Q000097:blood; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control; D010052:Ovariectomy; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000071681:Tartrate-Resistant Acid Phosphatase; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D043925:Angiogenesis Inducing Agents; D000893:Anti-Inflammatory Agents; D050071:Bone Density Conservation Agents; D005419:Flavonoids; D015850:Interleukin-6; D007527:Isoenzymes; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D015675:Osteocalcin; D019833:Genistein; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; C056599:icariin